Valeant Pharmaceuticals International VRX
The three reasons
- 1
Platform companies are undervalued because P/E ignores value from future acquisitions
- 2
Valeant earned >20% unlevered returns on $20bn+ of acquisitions since 2008
- 3
If VRX keeps compounding, stock is worth $330+ today vs. $223 current price
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Notable slides (8)
Notes
Landmark Ira Sohn 2015 presentation where Ackman introduced the 'Platform Value' concept as a valuation framework. Unusual structure: opens with three supporting case studies (Jarden '45x', PAH, Nomad) before pivoting to the headline pitch on Valeant (VRX) with the rhetorical 'What is going on here?' interlude on page 10. Pure long/bull thesis praising management (Mike Pearson, Martin Franklin) — not adversarial. Core innovation is arguing that traditional P/E understates serial acquirers by ignoring future capital-allocation option value. Cover slide is minimalist: just the number '45x' and the firm logo — a memorable opener. Campaign outcome famously disastrous: Valeant collapsed ~90% in 2015-2016 over pricing scandals and accounting issues, making this deck a frequently cited case study of narrative hubris in value investing. Document type 'conference_presentation' because delivered at Sohn. Date inferred from 'as of May 1, 2015' references throughout.